Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Studies have found that weight gain is common after people with HIV begin an antiretroviral in this class.
The FDA approves three new, cheaper combination ARV tablets.
The tablet contains the same combo as Symfi Lo (efavirenz/lamivudine/tenofovir disoproxil fumarate) but with a higher dose of efavirenz.
Symfi Lo contains efavirenz, lamivudine and tenofovir disoproxil fumarate (TDF); Cimduo contains TDF and lamivudine.
Long-term Viread (tenofovir disoproxil fumarate, or TDF) use is linked with a raised risk of end-stage liver cancer in HIV-positive people.
The most effective birth control methods for women with HIV are implants and injectable hormonal contraceptives.
An updated version of Viread (tenofovir) offers slightly better viral suppression and improves indicators of kidney and bone health...
Merck’s next-generation NNRTI doravirine (MK-1439) suppresses HIV as well as Sustiva (efavirenz) and leads to half the rate of side effects.
Drug-resistant strains of HIV continue to be transmitted in the UK, but this doesn’t appear likely to have a major effect on the treatment res...
Harvoni and the combination of Sovaldi and daclatasvir were the least likely to cause a severe reaction with the HIV regimens of a cohort of H...
Various HIV antiretrovirals are linked to a raised risk of cardiovascular problems, although the overall risk of such an outcome is still low.
Multi-antiretroviral combination tablets appear to combat HIV no better than regimens that include individual tablets.
A revision of U.S. HIV treatment guidelines has removed Atripla (efavirenz/tenofovir/emtricitabine) from the priority list of first-line antir...
For those with fully suppressed HIV, switching to a two-drug regimen of cabotegravir and Edurant works as well taking a triple regimen.
People who coinfected with HIV and hepatitis C looking to take the HCV drug Olysio may need to change HIV medications to avoid drug-drug...
Harvoni yielded a 96 percent cure rate among people with genotype 1 of hepatitis C, as well as a small number of those with genotype 4.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.